MetaCap

Erasca (ERAS) vs Liquidia (LQDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Erasca (ERAS) has outperformed Liquidia (LQDA) over the past year, gaining 366.1% versus a gain of 87.0%. Over five years, LQDA leads with a +1224.3% price change compared with -11.3% for ERAS. Liquidia is the larger company by market cap ($4.90 billion vs $4.78 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ERAS+366.10%LQDA+86.98%
+704%+329%-45%
Nov 21, 20251 yearNov 20, 2026
ERAS-24.51%LQDA+1177.70%
+2123%+962%-199%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ERAS versus LQDA key metrics
MetricERASLQDA
Share price$13.61$54.43
Market cap$4.78B$4.90B
1-day change-4.29%-3.88%
YTD return+265.86%+57.81%
1-year return+366.10%+86.98%
5-year return-11.28%+1224.33%
Forward P/E—15.12
EPS (TTM)$-0.97$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$158.32M
Revenue growth (YoY)—+1031.18%
Net income (latest FY)$-124.55M$-68.92M
Operating margin—-32.45%
Net margin—-43.53%
52-week high$24.28$93.61
52-week low$2.81$22.31
Distance from 52-week high-43.95%-41.85%
Analyst consensusbuybuy
Avg. price target upside+77.15%+21.50%
Average volume5.27M3.52M
Shares outstanding350.96M90.11M
Employees103216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ERAS has outperformed LQDA by 279.1 percentage points over the past year.

About Erasca

ERAS stock →

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

About Liquidia

LQDA stock →

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

ERAS vs LQDA FAQ

Which is bigger, Erasca or Liquidia?

Liquidia (LQDA) is larger, with a market capitalization of $4.90B compared with $4.78B for Erasca (ERAS).

Which stock has performed better over the past year, ERAS or LQDA?

ERAS returned +366.10% over the past 12 months, compared with +86.98% for LQDA (price return, excluding dividends). Past performance does not predict future results.

Are Erasca and Liquidia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons